Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58.

Itamar Raz Lawrence Alan Leiter Lawrence A Leiter Avivit CahnSabina A MurphyErica L GoodrichIlan YanuvAliza RozenbergDeepak L BhattDarren K McGuireJohn P H WildingIngrid A M Gause-NilssonAnna Maria LangkildeMarc S SabatineStephen D Wiviott

Published in: Diabetes care (2021)

In patients with T2D and MRF, dapagliflozin reduced the risk of HHF and adverse renal outcomes regardless of baseline characteristics. These analyses support the benefit of dapagliflozin for important outcomes in a broad primary prevention population.

Keyphrases

randomized controlled trial
clinical trial
adipose tissue
insulin resistance
glycemic control
open label
weight loss